Which clinical trials support sapropterin's neuro benefits?

Short answer: there isn’t robust, large-scale randomized evidence that sapropterin (BH4) provides clear, direct neurocognitive benefits in PKU. Most approved and published data come from metabolic outcomes (lower phenylalanine, diet tolerance) and a smaller number of secondary analyses of cognitive/neuropsychological effects in BH4 responders. The neurocognitive findings are inconsistent and often come from small or retrospective studies.

What the available evidence generally shows
- Primary trials in PKU focus on metabolic response (Phe reduction and the ability to relax diet) in BH4-responsive patients. Neurocognitive outcomes are rarely the primary endpoint.
- Some small pediatric studies and observational reports suggest possible improvements in certain cognitive domains (e.g., executive function, attention, processing speed) in BH4 responders who achieve and maintain lower Phe levels. However, results are not uniform across all studies and patient groups.
- In adults, data on neurocognitive benefits are even more limited and less consistent.
- Overall, any observed neurocognitive improvements are more plausibly linked to better metabolic control (lower brain Phe) rather than a direct, independent “neuroprotective” effect of sapropterin.

If you’d like, I can pull a list of specific trials (names, years, and key neurocognitive outcomes) and summarize their findings with citations. Tell me if you want PKU-focused trials only, or also data related to other BH4-related conditions (e.g., dihydropteridine reductase deficiency) where neuro effects have been discussed.